chufangao/CTO huggingface dataset:
Clinical trial NCT04303845: Erenumab For Treatment of Hemicrania Continua
Official title: Erenumab For Treatment of Hemicrania Continua
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: difficulty with recruitment
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-04
Primary completion date: 2022-04-06
Completion date: 2022-04-06
Limitations and caveats: Terminated study due to low enrollment
Plan to share individual participant data: NO
Clinical trial NCT04809012: Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Official title: An Open-label, Multicenter, Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Sponsor: Sorrento Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Intended to be replaced with another Protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-30
Primary completion date: 2024-06-30
Completion date: 2024-06-30
Clinical trial NCT03861039: A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Official title: A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 443.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-30
Primary completion date: 2021-01-26
Completion date: 2021-02-16
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04396366: Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis
Official title: A Randomized, Subject- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Patients With Bronchiectasis
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Strategic business decision
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-02
Primary completion date: 2023-06-15
Completion date: 2023-06-21
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT03986996: Antimicrobial Therapy for Ulcerative Colitis (UC)
Official title: Antimicrobial Therapy for Ulcerative Colitis : Evaluation of Two Antibiotic Combinations for Refractory Ulcerative Colitis
Acronym: UC
Sponsor: Wolfson Medical Center (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: There is no feasibility to conduct the study
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-25
Primary completion date: 2022-05-29
Completion date: 2022-05-30
Plan to share individual participant data: NO
Clinical trial NCT05170828: Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Official title: PRESERVE: A Multi-Center Trial Using Banked, Cryopreserved HLA-Mismatched Unrelated Donor Bone Marrow and Post-Transplantation Cyclophosphamide in Allogeneic Transplantation for Patients With Hematologic Malignancies
Sponsor: Ossium Health, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Change in Study Design
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-09-30
Primary completion date: 2024-03-31
Completion date: 2024-11-30
Plan to share individual participant data: NO
Clinical trial NCT03139747: UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Official title: UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Sponsor: Thomas Jefferson University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: lack of accrual reevaluating feasibility
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-03
Primary completion date: 2022-05-30
Completion date: 2022-05-30
Clinical trial NCT02971410: Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma
Official title: Overcoming Chemotherapy Resistance in Refractory Multiple Myeloma With Simvastatin, A Pilot Study
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: PI no longer interested in pursuing study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-30
Primary completion date: 2021-11-30
Completion date: 2021-11-30
Clinical trial NCT02038478: Allograft for Sickle Cell Disease and Thalassemia
Official title: Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-01-31
Primary completion date: 2021-01-31
Completion date: 2021-05-31
Clinical trial NCT02884206: Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Official title: A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Acronym: PERSPECTIVE
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 592.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-23
Primary completion date: 2022-05-16
Completion date: 2022-05-16
Baseline population: Baseline Participants are based on the Randomized population, as primary and secondary analysis are based on the Randomized Set
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT02035137: 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
Official title: NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma
Acronym: N2011-01
Sponsor: New Approaches to Neuroblastoma Therapy Consortium (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 114.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-07-31
Primary completion date: 2021-02-26
Completion date: 2021-02-26
Baseline population: The 111 patients described as baseline participants removes the 3 ineligible patients as provided in the initial row of the participant flow module.
Clinical trial NCT03769181: A Study of Isatuximab-based Therapy in Participants With Lymphoma
Official title: A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination With Other Anti-cancer Therapies in Participants With Lymphoma
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling the pre-planned interim analysis criteria or fulfilling the criteria but as per sponsor decision. It was not due to any safety concern
Enrollment: 58.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-12-11
Primary completion date: 2022-11-08
Completion date: 2022-11-08
Baseline population: Analysis was performed on all treated population which included all participants who signed the study informed consent and received at least 1 dose of the study treatment, either isatuximab or cemiplimab.
Limitations and caveats: The efficacy results observed in Cohorts B and C did not fulfill the pre-planned interim analysis criteria allowing the study to move to Phase 2 Stage 2 in these cohorts. The efficacy results observed in Cohort A1 and A2 fulfilled the pre-planned interim analysis criteria in Stage 1 to move to Phase 2 Stage 2 in these cohorts. However, the study was stopped for all the cohorts as per Sponsor's decision.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT01869374: Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults
Official title: Improving Outcomes in Geriatric Depression: Magnetic Seizure Therapy
Acronym: MSTvsEST
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-08-31
Primary completion date: 2017-07-31
Completion date: 2020-08-31
Plan to share individual participant data: NO
Clinical trial NCT03335020: Using Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Cardiovascular Disease
Official title: Assessment of Contrast-enhanced Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Arterial Wall Visualization and Stiffness in Patients With Fibromuscular Dysplasia...
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Closed by Investigator
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-04-01
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT04317781: Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
Official title: Tagraxofusp (SL-401) Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The protocol was terminated early due to slow participant accrual and the sponsor not willing to provide the study drug.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-27
Primary completion date: 2023-07-11
Completion date: 2023-07-11
Limitations and caveats: The protocol was terminated early due to slow participant accrual and the sponsor not willing to provide the study drug.~Stemline is the funder, not the sponsor.
Clinical trial NCT01555281: Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
Official title: Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy - A Single Arm Phase I/II Trial
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: In connection with the restructuring of SAKK, older ongoing studies were analyzed to determine whether a continuation of the trial would still add value to the data analysis, or whether they do not and could therefore be prematurely terminated.
Enrollment: 33.0 (ACTUAL)
Number of arms: 1.0
Start date: 2012-02-23
Primary completion date: 2022-06-08
Completion date: 2022-06-08
Plan to share individual participant data: NO
Clinical trial NCT04634110: Brigatinib Before Brain Irradiation Trial (B3i Trial)
Official title: Brigatinib Before Brain Irradiation Trial (B3i Trial): A Phase II Trial of Brigatinib Alone for Brain Metastases From ALK+ Lung Cancer
Sponsor: University of Colorado, Denver (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-17
Primary completion date: 2022-04-14
Completion date: 2022-04-14
Limitations and caveats: 1 subject enrolled then study terminated due to low accrual. No further analyses completed.
Plan to share individual participant data: NO
Clinical trial NCT04378010: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH
Official title: A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-alcoholic Steatohepatitis (NASH) (ARGON-2)
Sponsor: Enanta Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enanta Pharmaceuticals, Inc. made the strategic decision to discontinue the ARGON-2 study to prioritize combination treatment approaches. This decision was not based on safety concerns.
Enrollment: 98.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-01-27
Primary completion date: 2021-10-04
Completion date: 2021-11-30
Baseline population: NOTE: In the EDP-305 2mg arm 1 participant was randomized but not treated.
Limitations and caveats: No limitations reported for the study.
Plan to share individual participant data: NO
Clinical trial NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Official title: A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Acronym: QWINT-2
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 928.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-03
Primary completion date: 2024-04-10
Completion date: 2024-04-10
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04675983: A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
Official title: A Randomized, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Sintilimab Combined With Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ORIENT-106)
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to the company's development strategy adjustment, Innovent Biologics has decided not to continue this study after consultation with investigators
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-10
Primary completion date: 2023-02-12
Completion date: 2023-02-12
Clinical trial NCT04316598: Cannabis Effects on Electroencephalography
Official title: Monocenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess the Pharmacodynamic Effects of Cannabis on Neural Oscillations in Healthy Recreational Cannabis Users
Acronym: CEG
Sponsor: Parc de Salut Mar (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated by the sponsor in the context of COVID-19 pandemia
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-03
Primary completion date: 2020-07-09
Completion date: 2020-07-09
Plan to share individual participant data: NO
Clinical trial NCT04558216: Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
Official title: An Open-Label, Fixed-Sequence, Clinical Drug Interaction Study to Evaluate The Effect of a CYP3A-Inducer, Rifampin, on the Pharmacokinetics of Vonoprazan in Healthy Volunteers
Sponsor: Phathom Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Withdrawn due to unavailability of rifampin for clinical trial use
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-30
Primary completion date: 2021-02-07
Completion date: 2021-02-19
Plan to share individual participant data: NO
Clinical trial NCT01417546: NHS-IL12 for Solid Tumors
Official title: First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid Tumors
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 72.0 (ACTUAL)
Number of arms: 3.0
Start date: 2011-12-12
Primary completion date: 2021-06-02
Completion date: 2021-10-14
Clinical trial NCT05379179: Ketamine Pilot Study
Official title: Pilot Study: Ketamine for Acute Pain After Rattlesnake Envenomation
Sponsor: University of Arizona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: After 20 months of active enrollment and a lack of qualified/interested subjects, the Investigator, Meghan Spyres, MD, decided to terminate recruitment before meeting the stated enrollment objectives.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-20
Primary completion date: 2022-08-27
Completion date: 2022-08-27
Limitations and caveats: Significant limitations were not reaching the target number of patients, extremely low enrollment resulted in termination.
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to make IPD available.
Clinical trial NCT04140968: Progesterone and Resting Energy Expenditure
Official title: Impact of Progesterone Substitution in Luteal Phase on Resting Energy Expenditure in Women During Menopausal Transition.
Acronym: P4&REE
Sponsor: Insel Gruppe AG, University Hospital Bern (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: massive recruitment problems became apparent because of the strict inclusion criteria of our study.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-01
Primary completion date: 2021-05-27
Completion date: 2021-05-27
Plan to share individual participant data: NO
Clinical trial NCT05065463: To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.
Official title: A Single Dose, Non-randomised, Open-label, Parallel Group Study to Assess the Pharmacokinetics, PCSK9 Reduction, Safety, and Tolerability of AZD8233 in Participants With Severe Renal Impairment, End Stage Renal Disease and Healthy Participants as Controls
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: A decision has been taken to discontinue the development of AZD8233 (PCSK9-ASO for sc administration) due to low likelihood of demonstrating a benefit significantly above the current standard of care for patients with high-risk hypercholesterolemia.
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-08-10
Primary completion date: 2022-11-23
Completion date: 2022-11-23
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the requests portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04527471: Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
Official title: A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19
Sponsor: Verona Pharma plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 45.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-04
Primary completion date: 2021-02-15
Completion date: 2021-05-01
Limitations and caveats: This was an un-powered pilot study of ensifentrine pMDI in patients hospitalized for moderate COVID-19 infection.
Plan to share individual participant data: NO
IPD sharing description: Verona Pharma will not be sharing individual deidentified participant data or other relevant study documents.
Clinical trial NCT03874806: Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block
Official title: Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block: a Comparison of Bolus Dosing and Continuous Infusion
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Did not receive funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-01
Primary completion date: 2020-07-01
Completion date: 2020-12-31
Plan to share individual participant data: NO